Medtronic (MDT) Net Equity Issued and Repurchased (2014 - 2026)

Medtronic has reported Net Equity Issued and Repurchased for 13 years, with the latest figure at $97.0 million in Q2 2026.

• Quarterly Net Equity Issued and Repurchased fell 10.19% year-over-year to $97.0 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $516.0 million (up 1.57% YoY) and the FY2026 annual result came in at $516.0 million, up 1.57% from the prior year.
• Net Equity Issued and Repurchased eased to $97.0 million in Q2 2026 per MDT's latest filing, from $164.0 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $168.0 million in Q1 2025 and troughed at $43.0 million in Q3 2022.
• A 5-year average of $98.4 million and a median of $92.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2022 and 2025: Net Equity Issued and Repurchased tumbled 64.1% in 2022, then soared 194.74% in 2025.
• Over 5 years, Net Equity Issued and Repurchased stood at $110.0 million in 2022, then slumped by 34.55% to $72.0 million in 2023, then surged by 98.61% to $143.0 million in 2024, then advanced by 11.89% to $160.0 million in 2025, then tumbled by 39.38% to $97.0 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $97.0 million, $164.0 million, and $160.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.